anemia%20-%20iron-deficiency
ANEMIA - IRON-DEFICIENCY
Anemia is a condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) and/or hematocrit (intact RBC in blood) making it insufficient to address the physiologic needs of the body.
Iron-deficiency anemia is the anemia that resulted from inadequate iron supplementation or excessive blood loss.
It is the most common nutritional disorder worldwide and accounts for more than half of anemia cases.
It is prevalent among preschool children and pregnant women.

Definition

  • A condition wherein the blood has low levels of red blood cells (RBC), hemoglobin (oxygen-carrying pigment in whole blood) or hematocrit (intact RBC in the blood) making it insufficient to address the physiologic needs of the body
  • Based on WHO, anemia is having hemoglobin concentration:
    • Men (>15 years old): <13 g/dL
    • Women (non-pregnant, >15 years old): <12 g/dL
    • Women (pregnant): <11 g/dL (declines to 0.5 g/dL in the 2nd trimester of pregnancy)
    • Children (12-14 years old): <12 g/dL
    • Children (5-11 years old): <11.5 g/dL
    • Children (6 months - 4 years old): <11 g/dL

Etiology

Causes of Anemia

  • Normocytic anemia when RBC morphology is unremarkable 
    • Blood loss - most common cause
    • Decreased RBC production due to low RBC production or destruction of precursors of RBC within the bone marrow, eg chronic disease
    • Increased RBC destruction, eg hemolysis
  • Macrocytic anemia wherein the RBC is larger than the nucleus of a small lymphocyte on a peripheral smear due to:
    • Megaloblastic causes: Folate and vitamin B12 deficiency, HIV infection, rare inborn errors of metabolism, myelodysplastic syndrome or congenital dyserythropoietic anemia
    • Nonmegaloblastic causes: Marked reticulocytosis, aplastic anemia, abnormal nucleic acid metabolism of erythroid precursors interfering with nucleic acid synthesis, abnormal RBC maturation, other causes such as Down syndrome, alcohol abuse, liver disease and hypothyroidism
  • Microcytic anemia when RBCs appear smaller due to the following pathologic processes:
    • Reduced iron availability/iron-deficiency anemia
    • Acquired disorders of heme synthesis, eg thalassemia 
    • Reduced globin production
    • Rare congenital disorders including sideroblastic anemias, porphyria, and defects of iron absorption transport, utilization and recycling
    • Inflammation or chronic disease
    • Lead poisoning

Signs and Symptoms

  • Primary symptoms include: Dyspnea (exertional or at rest), fatigue, palpitations, headache, faintness or lightheadedness, tinnitus, anorexia, gastrointestinal (GI) disturbances, loss of libido
  • Symptoms of severe anemia include: Lethargy, confusion, tachycardia, retinal hemorrhage that may lead to life-threatening complications such as congestive heart failure, angina, arrhythmia and/or myocardial infarction
  • Symptoms can be due to decreased oxygen delivery to tissues and in patients with acute and marked bleeding, the added insult of hypovolemia
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Kavitha G. Shekar, 04 May 2016
Cannabis use during pregnancy increases the risk of maternal anaemia, and causes several adverse outcomes in infants like low birth weight (LBW), and increased neonatal intensive care unit (NICU) admissions, show findings of a systematic review and meta-analysis.
26 Feb 2017
Placement of cervical pessary in women with short cervices and singleton pregnancies does not lower the risk of having preterm births, according to the results of a meta-analysis.
01 Jan 2015
Iron supplementation has long established its role from among women of child-bearing age. This study, however, looked into the effect of zinc when in combination with iron.
Roshini Claire Anthony, 07 Sep 2016

Estrogen receptor α (ESR1) mutations Y537S and D538G are associated with reduced overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, according to findings of a secondary analysis of the BOLERO-2* clinical trial.